Inflammatory myopathies are a group of autoimmune muscle diseases characterised by proximal muscle weakness and inflammation. The three main types -- polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) -- share the feature of muscle weakness as the dominant walking-limiting symptom, but differ substantially in prognosis, treatment response, and therefore the walking aid trajectory.
How Inflammatory Myopathies Affect Walking
All three types cause proximal muscle weakness that specifically impairs walking:
- Hip flexors: Weakness here makes it difficult to lift the leg during the swing phase, causing difficulty on stairs and on uneven terrain where the hip must be flexed to clear the ground
- Quadriceps: Weakness here causes the knee to buckle during the stance phase (the weight-bearing phase). Patients may need to place a hand on the knee to push it into extension when rising from a chair or descending stairs
- Gluteal muscles: Weakness here causes a Trendelenburg gait (pelvic drop on the opposite side) and trunk sway during walking
Polymyositis and Dermatomyositis: Treatable, Recoverable
PM and DM are inflammatory conditions that respond, often substantially, to immunosuppressive treatment:
- High-dose corticosteroids (prednisolone 1mg/kg/day initially) are the primary treatment, producing muscle strength recovery over weeks to months
- Steroid-sparing agents (azathioprine, methotrexate, mycophenolate) are added to reduce long-term steroid load
- Biologics (rituximab, intravenous immunoglobulin) are used in refractory cases
- Walking capacity can improve substantially with treatment, and cane use may reduce or be discontinued as muscle strength recovers
However, during active disease before treatment response, and during treatment with high-dose corticosteroids (which paradoxically cause steroid myopathy -- adding to the inflammatory myopathy), walking capacity is significantly impaired and a cane is often necessary.
Inclusion Body Myositis (IBM): Different Prognosis
IBM is fundamentally different from PM and DM:
- Typically affects older adults (over 50, predominantly male)
- Does NOT respond to immunosuppressive treatment -- unlike PM and DM, IBM is essentially non-treatable with current therapies
- Has a characteristic pattern: finger flexor weakness (asymmetric), quadriceps weakness (particularly), and dysphagia
- The quadriceps weakness in IBM is often severe and early -- the knee buckle during walking is a hallmark feature
- IBM is slowly progressive over years to decades; walking aid needs increase progressively
Inflammatory Myopathy Type and Walking Aid
| Type | Prognosis | Cane Duration |
|---|---|---|
| Polymyositis (PM) | Often responds to immunosuppression | During active disease; reassess as strength recovers |
| Dermatomyositis (DM) | Often responds to immunosuppression | During active disease; reassess as strength recovers |
| Inclusion body myositis (IBM) | Does not respond to treatment; progressive | Long-term; increasing need over years |
| PM/DM on high-dose steroids | Steroid myopathy adds to weakness | During steroid phase; reduces as steroids taper |
Explore the DaiWalk cane collection. Related: Walking Cane for Polymyositis | Walking Cane and Steroids
